Kotak downgrades Lupin to ‘Reduce’, citing USFDA action

By: | Updated: March 18, 2016 9:32 AM

Lupin Pharmaceuticals (LPC) had a double whammy as news of a form 483 at its key Goa facility led to fears about negative FDA action, though we are yet to see the 483.

lupin, bse sensex, nse niftyLupin Pharmaceuticals (LPC) had a double whammy as news of a form 483 at its key Goa facility led to fears about negative FDA action, though we are yet to see the 483.

Lupin Pharmaceuticals (LPC) had a double whammy as news of a form 483 at its key Goa facility led to fears about negative FDA action, though we are yet to see the 483. At the same time, Valeant reported $86 million revenues for Glumetza in 4QCY16, far lower than consensus estimates of $100-150 million market size, and reflecting our views of 70% rebating. We now see a possibility of 10% downgrade to FY17 consensus EPS on back of lower Glumetza sales. Reduce.

In an inspection carried out last week, LPC’s Goa facility received a 483 with 9 observations. The inspection follows a July 2015 inspection when LPC was handed 9 observations. The Goa facility is LPC’s flagship facility with key products, making several key products such as Fortamet ER, Lisinopril, Glumetza, etc and on our estimates, will account for 40-50% of LPC’s US sales in FY16.

Worries are amplified due to high reliance on Goa for several of LPC’s key ANDA filings (esomeprazole, sevelamer, etc.). The 8-month time gap between two inspections has left investors baffled, and we believe the recent inspection might have been a prior approval inspection for an ANDA, though we note that this is the third instance observed by us when a company has been re-inspected in less than 12 months.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition